Upstream Bio, Inc. (UPB) stock intrinsic value fair value estimate & owner earnings analysis

Upstream Bio is a clinical-stage biotechnology company with one drug, verekitug, an antibody that blocks the receptor for TSLP, an inflammatory signal. Blocking TSLP is a proven approach: Amgen and AstraZeneca's Tezspire has been approved for severe asthma since 2021 and for chronic rhinosinusitis with nasal polyps since October 2025, and reached about $1.9 billion in combined sales in 2025. Upstream sells nothing. Its only revenue, about $2.9 million in 2025, is reimbursement from its Japanese partner Maruho for development work. Maruho holds Japanese rights royalty-free, so Japan would add nothing to Upstream's future sales. The science has gone well so far. The Phase 2 VALIANT trial in severe asthma (February 2026) showed a 56% reduction in asthma attacks at 100 mg every 12 weeks, and the Phase 2 VIBRANT trial in nasal polyps (September 2025) succeeded, with about 80% of treated patients improving meaningfully. After meeting with the FDA, the company said on September 1, 2026 that it will run one Phase 3 trial in each disease, about 1,500 patients in total, testing a higher 400 mg quarterly dose with 48-week endpoints, starting in the first quarter of 2027. That puts the earliest launch in 2030. A 481-patient Phase 2 trial in COPD reads out in the second half of 2027. As a business, Upstream consumes cash. Owner earnings, meaning operating cash flow with stock compensation charged as the real cost it is, were about -$37 million in 2023, -$68 million in 2024 and -$145 million in 2025, and operating cash outflow was $83.5 million in the first half of 2026. At June 30, 2026 the company held $261.3 million in cash and short-term investments, about $4.77 per share, against $10.2 million of ordinary liabilities and no borrowings; at the first-half pace, roughly $4.00 per share remained at the end of September. The company says this cash funds operations through 2027. The Phase 3 trials run well past that, into a BLA filing and a 2030 launch, so at even today's spending pace roughly $330 million or more of new capital is needed in 2028-2029 before a single dose is sold. We value only what the business has in hand: contracts, licenses, demonstrated earning power. A drug that has not yet started Phase 3 does not qualify, however promising its data. That is not a claim that verekitug is worthless; it is that its commercial value depends on trials, an FDA decision and a launch into a market Tezspire already leads, and none of those has happened. Meanwhile the company's plan is to spend essentially all of its current cash on those trials, so the cash on the balance sheet today mostly measures what is about to be spent, not what an owner keeps. Bear case (about $0 per share): The Phase 3 programs, roughly twice the size of the Phase 2 work, push spending above today's pace; the company raises equity in 2027-2028 on poor terms; and at least one pivotal trial disappoints. TSLP drugs do not win every trial: Tezspire's own steroid-sparing Phase 3 (SOURCE) and its first COPD study (COURSE) both missed their main goals. Today's shareholders' cash and new investors' cash are both spent with nothing left for current holders. With no debt, the floor is zero rather than below it. Base case (about $0.10 per share): The company follows its stated plan. About $42 million goes out in the fourth quarter of 2026 and Phase 3 start-up uses nearly all the rest in 2027, consistent with management's statement that cash lasts through 2027, leaving a cushion of perhaps $5 million. No value is credited for verekitug. Bull case (about $0.40 per share): Spending runs tighter than guided as the Phase 2 trials wind down (second-quarter 2026 research spending was already slightly below the prior year) and Phase 3 costs ramp gradually with enrollment, leaving roughly $20-25 million at the end of 2027. Even here nothing is credited for a successful Phase 3, a partnership or a sale, because none has happened. Any eventual product would also owe Regeneron a mid-single-digit royalty and Lonza a small manufacturing royalty. Margin of safety price: Today nothing in the business produces cash an owner can count on, so no margin-of-safety price applies on price alone. A margin-of-safety price applies only after verekitug is approved and has shown at least two consecutive quarters of real U.S. sales totaling at least $40 million, with no more than about 120 million shares outstanding (the company will likely need around $500 million of new capital to reach that point, roughly doubling today's share count). On that condition, the margin of safety price is $4.50 a share, lower in proportion if dilution is heavier. If the launch then follows a path we can support from Tezspire's record, about $700 million of U.S. peak sales for a later entrant whose advantage is quarterly at-home dosing, owner earnings would reach roughly $180 million a year by about 2034 after royalties, manufacturing, a sales force and ongoing research, and hold until U.S. biologic exclusivity ends around 2042. That would make the shares worth about $12, and from $4.50 that path implies roughly 25% a year, leaving room for the ramp to run a year late. The risk we are most likely to be wrong about is the launch itself, against Tezspire and against twice-yearly rivals from GSK and Sanofi: because selling costs are largely fixed, a launch at half that level would roughly break even and leave the shares worth little more than cash, about $1.50-2.00, which from $4.50 implies a substantial loss, though not a wipeout. The company pays no dividend, so any return rests on the launch working. Our previous estimates for Upstream were made on a different basis and are not comparable. The business facts that have changed since then are the larger 1,500-patient Phase 3 plan with a 2030 earliest launch, and a further quarter of cash spent.